How Rasagiline works

Rasagiline (Rasagiline) is a second-generation potent and selective monoamine oxidase b inhibitor. Parkinson's disease (PD) is a chronic, progressive, incurable neurodegenerative disease characterized by bradykinesia, rigidity, resting tremor and postural instability. Rasagiline at both 1 mg and 2 mg/day doses can improve UPDRS scores in PD patients, with no significant difference between the two doses. This drug is beneficial for patients receiving both monotherapy and combination therapy.

UPDRS Part 1 (mental status) scores improved in the 1 mg/day rasagiline group but not in the 2 mg/day rasagiline group. UPDRS Part II (ADL) and Part III (Exercise) scores improved significantly in the 1 mg/day and 2 mg/day rasagiline treatment groups, with no significant differences between study doses. Overall, rasagiline was well tolerated, with common side effects including nausea, headache, dizziness, and drowsiness. In the included studies, no significant differences in complication rates were found between the placebo and rasagiline treatment groups.

The original drug of rasagiline has been launched in China and has entered the category of Class B medical insurance. The common name is rasagiline mesylate tablets, and the specifications areThe price of each box of 1mg*14 tablets may be around RMB 600. The price of the Turkish version of rasagiline's original drug, 1mg*30 tablets, per box sold overseas may be around RMB 310 (the price may fluctuate due to exchange rates). There are also generic drugs produced in other countries. The price of a box of 1mg*100 tablets produced by an Indian pharmaceutical factory may be around RMB 240 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs. For specific prices and drug information, please consult Yaode Medical Consultants.